Business   

Dr. Reddy's loses to Pfizer in drug ruling

By Our Special Correspondent

HYDERABAD, FEB. 28. Dr. Reddy's Laboratories announced that the U.S. Court of Appeals for the Federal Circuit reversed a lower court ruling and determined that the patent extension covering Pfizer's Norvasc (amlodipine besylate) is applicable to Dr. Reddy's amlodipine maleate.

G. V. Prasad, Chief Executive Officer, Dr. Reddy's, in a press release here on Saturday said they were disappointed by the court decision and had expected that the views expressed by the Chief Judge in the dissent would have been the position of the majority.

He said despite today's ruling, the company remained committed to investing resources to create a sustainable U.S.-based business of specialty products and new chemical entities and generic medicines. He said the company was making good progress in advancing its product pipeline, which now includes several projects under development targeting high-potential primary care and select specialty segments.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary | Updates: Breaking News |

Stories in this Section

• Bharti Televenture's new initiatives
• IPCL issue raises Rs. 1,200 cr.
• India is entrepreneur driven, says Jaitley
• Hemogenomics centre in Bangalore
• Banks asked to use NBFCs for transport finance
• Dr. Reddy's loses to Pfizer in drug ruling
• Judge drops fraud charge against Martha Stewart
• Forex reserves exceed $107 b
• Lupin pact with Baxter
• Unichem to set up U.S. subsidiary

Copyright © 2004, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu